Nusano Announces Isotope Availability
High-volume, breakthrough radioisotope production platform to enable innovation in life sciences and industrial applicationsVALENCIA, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE)...
Pharmaceutical
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to...
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of...
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) --...
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc....
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression...
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for...
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of...
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential...
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC...
Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O’Neill, Ph.D.
Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with...
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560...
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to...
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001,...
FitSpresso Review: Why Fitspresso Coffee Loophole Is Better Than Other Weight Loss Supplement in 2025?
FitSpresso is the perfect choice for those seeking an effective solution to achieve healthy weight loss. NEW YORK CITY, NY...
Annexus Health Rings In 2025 By Surpassing $6 Billion in Patient Financial Assistance Awards Secured
Driven by a network of more than 4,200 sites of care now using the AssistPoint® platform to manage and secure...
CellFE® and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow
ALAMEDA, Calif., Jan. 9, 2025 /PRNewswire/ -- CellFE®, a leader in non-viral gene editing technology, and Syenex, a pioneer in...
Hospital PMI® at 56.3%; December 2024 Hospital ISM® Report On Business®
TEMPE, Ariz., Jan. 9, 2025 /PRNewswire/ -- Economic activity in the hospital subsector grew in December for the 16th consecutive month...